Press Release Forum [pressreleaseforum.com] Forum Index

Press Release Forum [pressreleaseforum.com]
Free Press Release Distribution

A site of EPR Network

 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 

Real Time Press Release Distribution is here. Try it out, it's free!

 

AnaSpec Introduces Ten New Catalog Peptides

 
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases
View previous topic :: View next topic  
Author Message
anaspec



Joined: 15 Aug 2006
Posts: 238
Location: 34801 Campus Drive, Fremont, CA 94555

PostPosted: Mon Jul 23, 2007 11:42 am    Post subject: AnaSpec Introduces Ten New Catalog Peptides Reply with quote

July 20, 2007 – San Jose, CA

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new peptides for drug discovery research.


MUC4 - Cat# 61339
This peptide is derived from the tandem repeat of Muc 4 mucin protein. Mucins are highly O-glycosylated proteins which polymerize through the formation of disulfide bonds to form a gel that is secreted onto the surface of glandular epithelia. MUC4 mucin is a high molecular weight membrane-bound glycoprotein. It is aberrantly expressed in pancreatic tumors and tumor cell lines with no detectable expression in normal pancreas.
Sequence: TSSASTGHATPLPVTD

MUC2 - Cat# 61337
This peptide is derived from the tandem repeat of Muc 2 mucin protein. MUC2 is characterized by tandem and irregular repeat sequences rich in threonine and serine; the potential sites of attachment of the oligosaccharide chains. The primary function of the MUC2 gene product is to provide a protective barrier between the epithelial surfaces and the gut lumen. There is decreased expression of MUC2 in colonic cancer and defective polymerization of secreted mucin in ulcerative colitis. Mucins play a protective role for the adjoining epithelial tissues under normal physiological conditions; whereas an altered expression of mucins is often associated with carcinomas and neoplastic lesions.
Sequence: PTTTPISTTTVTPTPTPTGTQT

MUC3 - Cat# 61338
This peptide is derived from the tandem repeat of Muc 3 mucin protein. MUC3 is a membrane associated mucin of the small intestine. Probiotic microbes induce MUC3 mucin transcription and translation with extracellular secretion of the MUC3 mucins. Mucins are highly O-glycosylated proteins which polymerize through the formation of disulfide bonds to form a gel that is secreted onto the surface of glandular epithelia. Mucins play a protective role for the adjoining epithelial tissues under normal physiological conditions; whereas an altered expression of mucins is often associated with carcinomas and neoplastic lesions.
Sequence: HSTPSFTSSITTTETTS

MUC6a - Cat# 61340
This peptide is derived from the tandem repeat of Muc 6 mucin protein. Mucins are highly O-glycosylated proteins which polymerize through the formation of disulfide bonds to form a gel that is secreted onto the surface of glandular epithelia.
Sequence: SFQTTTTYPTPSHPQTTLP

MUC6b - Cat# 61341
This peptide is derived from the tandem repeat of Muc 6 mucin protein. MUC6B secretory mucin gene is expressed in a wide variety of epithelial tissues. In general; down-regulation of MUC6’s may contribute to malignant transformation of gastric epithelial cells and underlie the molecular bases of growth; invasion; metastasis and differentiation of gastric carcinoma. Down-regulation of MUC6 is associated with disease progression to adenocarcinoma of the esophagus.
Sequence: TSLHSHTSSTHHPEVPT

Muc7 - Cat# 61342
MUC7 gene encodes a low-molecular-mass mucin glycoprotein that functions in modulation of microbial flora in the oral cavity and respiratory tracts. MUC7 gene expression is tissue- and cell-specific; with dominant expression in salivary gland acinar cells. In the lungs; MUC7 is expressed within the respiratory epithelium at the level of the bronchioles. MUC7 peptides exhibit a preferential antibacterial activity for different strains. This peptide fragment of the Muc 7 was used to assay pp-GalNAc-T activity. Gene expression of MUC7 was detected in bladder cancer cell lines and samples of invasive transitional cell carcinomas.
Sequence: PTPSATTPAPPSSSAPPETTAA

MUC5AC-13 - Cat# 61333
This N-acetyl galactosamine (GalNAc)-modified MUC5AC mucin peptide contains the single site of threonine 13 labeled with GalNAc (T*). Polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) catalyzes the transfer of GalNAc from the nucleotide sugar UDP-GalNAc to threonine. The MUC5AC gene is mainly expressed in gastric and tracheo-bronchial mucosae; and some tumors.
Sequence: GTTPSPVPTTST-T*-SAP

gp100 (177–186) - Cat# 61505
This is a fragment of the gp100 antigen recognized by CB8+ T cells. Antigen gp100 represents a class of tumor antigens with shared expression on melanomas as well as on melanocytes; the cells of origin of this cancer. This is an HLA-A2-restricted peptide.
Sequence: AMLGTHTMEV

[Ile161]MAGE-A2 (157-166) - Cat# 61504
This is a MAGE-A2 157 peptide with the Val to Ile substitution at position 161 of the wild type melanoma antigen; residues 157 to 166. It is one of the peptide analogs that carry substitutions at residues other than the main major histocompatibility complex anchors. The MHC binding affinity of this heteroclitic analog can be measured and compared with the unmodified wild-type counterpart. This analog binds to HLA-A2.1 with lower affinity.
Sequence: YLQLIFGIEV

Beta-Amyloid (16-20); all d-isomers - Cat# 61343
This peptide is a central hydrophobic motif of amyloid beta peptide containing D-amino acid residues. The L-isomer peptide may function as a self-recognition element during beta-amyloid assembly into fibers. Short peptides incorporating this motif can bind to the ~40amino acid residue Alzheimer b-amyloid peptide and disrupt amyloid fibril formation. Replacing L- with D-amino acids could stabilize such peptides and permit their evaluation as therapeutic agents for Alzheimer's.
Sequence: KLVFF

For more information visit http://www.anaspec.com/products/new.asp?l=1

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

For more information visit www.anaspec.com
_________________
Ping Yang
Marketing Speialist
34801 Campus Drive
Fremont, CA 94555
1-800-452-5530 (Toll free)
1-510-791-9560 (Tel)
1-510-791-9572 (Fax)
ping@anaspec.com
www.anaspec.com
Back to top
View user's profile Send private message Send e-mail Visit poster's website
Display posts from previous:   
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases All times are GMT - 4 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum

Submit Press Release (Free)Submit Press Release